Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds

The discovery of inhibitors for oncogenic signalling pathways remains a key focus in modern oncology, based on personalized and targeted therapeutics. Computational drug repurposing via the analysis of FDA-approved drug network is becoming a very effective approach to identify therapeutic opportunit...

Descripción completa

Detalles Bibliográficos
Autores principales: Carrella, Diego, Manni, Isabella, Tumaini, Barbara, Dattilo, Rosanna, Papaccio, Federica, Mutarelli, Margherita, Sirci, Francesco, Amoreo, Carla A., Mottolese, Marcella, Iezzi, Manuela, Ciolli, Laura, Aria, Valentina, Bosotti, Roberta, Isacchi, Antonella, Loreni, Fabrizio, Bardelli, Alberto, Avvedimento, Vittorio E., di Bernardo, Diego, Cardone, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312272/
https://www.ncbi.nlm.nih.gov/pubmed/27542212
http://dx.doi.org/10.18632/oncotarget.11318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312272/
https://www.ncbi.nlm.nih.gov/pubmed/27542212
http://dx.doi.org/10.18632/oncotarget.11318

Ejemplares similares